Ulcerative
colitis (UC)

Crohn’s
disease (CD)

Irritable Bowel Syndrome
(IBS) pain

elevate-logo

Rise up Against
Ulcerative Colitis

ELEVATE UC is a Phase 3 program that includes ELEVATE 52, a 52-week induction and maintenance study, and ELEVATE 12, a 12-week induction study. The ELEVATE UC program is evaluating the efficacy and safety of once-daily, oral etrasimod* in patients with moderately to severely active UC.

  • Patients can remain on 5-aminosalicylic acid (5-ASA) and low-dose corticosteroids throughout the trial
  • Patients are randomized 2:1 to etrasimod* and placebo
  • The treat-through design of the ELEVATE 52 trial does not re-randomize patients at the transition from induction to maintenance
  • Patients are eligible to enter an open-label extension and receive investigational drug for up to 5 years

Etrasimod is an investigational drug and is not currently approved for use by any regulatory agency. This information is not intended to promote or recommend etrasimod for any use.

cultivate-logo

Addressing the Root
of Crohn’s Disease

CULTIVATE is a Phase 2/3 clinical trial program evaluating the efficacy and safety of once-daily, oral etrasimod* in patients with moderately to severely active CD.

  • The CULTIVATE clinical trial program is designed as a Phase 2/3 program to facilitate an operationally seamless transition from the Phase 2 portion of the study to the Phase 3 portion
  • The operationally seamless design helps ensure continuity for patients, investigators, and study staff, and maintains patient access to investigational study drug throughout the development process

Etrasimod is an investigational drug and is not currently approved for use by any regulatory agency. This information is not intended to promote or recommend etrasimod for any use.

captivate_logo

Take a Stand
Against IBS Pain

CAPTIVATE is a Phase 2 clinical program evaluating the efficacy and safety of oral olorinab* in patients experiencing abdominal pain associated with IBS.

  • This dose-ranging study includes 1 placebo treatment group and 3 investigational treatment groups; participants have a 75% chance of being randomized to an investigational treatment group
  • Patients completing the study have an opportunity to enroll in the long-term extension (LTE) and receive investigational treatment for an additional 52 weeks

Olorinab is an investigational drug and is not currently approved for use by any regulatory agency. This information is not intended to promote or recommend olorinab for any use.

For Medical Information, contact us at medinfo@arenapharm.com